Roussel Uclaf

In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought by Hoechst AG in 1997) as a salesman in Australia.^[2][4] In 1996, he became General Manager of Hoechst Marion Roussel in Australia, moving to Tokyo in April 1997.^[5]

Aventis

In 2000 he moved to Aventis in America, becoming chief operating officer of Aventis USA in 2002, which became Sanofi Aventis USA in 2004.^[6][7]

Roche

He joined Roche in 2006 as head of marketing.^[8] From April 2009 to 2010, he was chief executive of the Roche subsidiary Genentech. He rejoined Roche Pharma AG in 2010 as chief operating officer.^[9]

AstraZeneca

In August 2012 he was named as the new chief executive of AstraZeneca,^[10] the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012.^[11][12]

In July 2017, it was reported that Soriot would become the next CEO of Israel-based Teva Pharmaceutical Industries, succeeding Erez Vigodman, though this was soon denied.^[13][14][15]

In September 2018, he made headlines commenting on his pay of £9.4m in salary and bonuses. 'The truth is I’m the lowest-paid CEO in the whole industry', he said. 'It is annoying to some extent. But at the end of the day it is what it is.'^[16]

In 2023, Soriot was the highest paid CEO of the major European pharmaceutical companies, as he earned $21.3 million.That was a nearly 12% increase over 2022.^[17]